Data on long-term follow-up of donors for hematopoietic stem cell transplantation (HSCT) are limited. Donors of 612 adult allogeneic HSCT were studied, at a median of 81 (14-181) months post-HSC donation. Nine donors had severe health problems. Five donors died from aggressive malignancies or terminal illness, at a median of 41 (16-57) months post-donation. Notably, all their recipients had leukemic relapses. In contrast, donors of recipients in remission were all living. This observation might be due to an inherent depressed immunosurveillance in the donors, or selection of donors with suboptimal health for desperate patients with poor risks pre-HSCT.
Introduction
A therapeutic benefit of allogeneic hematopoietic stem cell transplantation (HSCT) in hematologic malignancies relies putatively on control of residual neoplastic cells by donorderived immunocompetent cells. Donors may be human leukocyte antigen compatible siblings or matched unrelated donors (MUD). Health screening is required in donor selection. 1 Similar to other organ donation, stress is placed on infective risks. 2 Guidelines on donor selection based on other medical conditions are scanty. 3, 4 After HSC donation, long-term follow-up of donors is rarely undertaken.
Increasingly, donors are recalled for further HSC or lymphocyte donations for graft failure or disease relapses. Therefore, donor health conditions after HSC donations have assumed greater importance. We report the occurrences of severe health problems in donors for a cohort of HSCT recipients, and relate them to recipient outcome.
Materials and methods

Recipients
Between June 1990 and June 2004, 612 adult allogeneic HSCT recipients were treated. The diagnoses, conditioning, prophylaxis for graft-versus-host disease (GVHD), incidence of GVHD and median survival have been reported. 5 Their underlying diagnoses included acute myeloid leukemia (AML, n ¼ 236), acute lymphoblastic leukemia (ALL, n ¼ 86), chronic myeloid leukemia (CML, n ¼ 194), lymphoma (n ¼ 39), myeloma (n ¼ 37) and severe aplastic anemia (n ¼ 20). For AML and ALL, the percentage of cases transplanted beyond first remission (CR1) were 58 and 36%, respectively, whereas 27% of CML cases received HSCT beyond first chronic phase (CP). A total of 266 patients had died from treatment-related mortality (n ¼ 71), disease relapse (n ¼ 124), GVHD (n ¼ 44) and other causes (n ¼ 27). The median follow-up of living patients was 42 (3-138) months. Donors Donors were siblings (n ¼ 488), parents or children (n ¼ 6), and MUD (n ¼ 118). Donor health was ascertained by reevaluation during salvage protocols (n ¼ 110), direct and/or telephone interview (n ¼ 384), and update from the Hong Kong Marrow Match Foundation for local MUD (n ¼ 91). Forty-seven donors could not be found. Information on overseas MUD was not available (n ¼ 27). Statistical calculations were performed using Cox model Kaplan Meier actuarial analysis (SPSS 10.0, Chicago, IL, USA).
Results
Recipients and donors
There were 360 male and 252 female recipients, at a median age of 45 (18-65) years; and 266 male and 346 female donors, at a median age of 32 (8-60) years. HSC was harvested from the marrow (n ¼ 558) or peripheral blood (n ¼ 54). Donor recall occurred in 161 cases (HSC to support chemotherapy or second HSCT for acute leukemia, n ¼ 103; donor lymphocyte infusion, DLI, for chronic myeloid leukemia, CML, n ¼ 58), with 154 donors actually proceeding further to donate HSC or lymphocytes.
Donor health
At a median donor follow-up of 81 (14-181) months, major and fatal health problems occurred in nine donors ( Table 1) . The initial source of HSC was marrow (n ¼ 8) and the peripheral blood (n ¼ 1, case 6). Three donors also further donated lymphocytes (case 2, twice) or granulocyte colonystimulating factor mobilized peripheral blood HSC (case 4, once; case 5, twice). Five sibling donors had died (cases 1-5), whose recipients all had leukemic relapses. Significant health problems in three other donors included nonfatal solid tumors (n ¼ 2) and homicide (n ¼ 1). One MUD reported a cervical intraepithelial neoplasm 2 years postdonation. For other donors, 395 were asymptomatic, whereas 44 reported minor complaints (backpain, n ¼ 13; malaise, n ¼ 6; frequent infections, n ¼ 5; poor memory, n ¼ 5; miscellaneous, n ¼ 15). In 47 deceased recipients, their donors could not be traced.
Donor health and recipient outcome
Notably, death occurred only to donors whose recipients ultimately had leukemic relapses (cases [1] [2] [3] [4] [5] . Death occurred at a median of 41 (16-57) months post-donation, attributable to aggressive carcinomas in four cases. Three of them had a prior history of or risk factors for these cancers. All five recipients relapsed in the absence of GVHD, at a median of 12 (6-36) months post-HSCT. Before HSCT, two recipients had frank relapse (cases 2, 4), and one recipient with Philadelphia chromosome positive acute lymphoblastic leukemia (case 1) had molecular disease. Case 4 had leukemic relapse of donor origin, the donor having died from bronchogenic carcinoma. 6 In contrast, for recipients without relapse, no donor death was observed (P ¼
Discussion
Donor screening aims to protect both donors and recipients. 1 Prospective donors in poor health are usually not selected. As in other organ donations, donors with previous malignancies are excluded. However, if these potential donors are the only ones available for recipients in dire conditions, selection criteria may be relaxed. 7 Donors with previous malignancies in prolonged remission Table 1 Major health problems in nine donors after donation of hematopoietic stem cells may be considered. However, our results suggested that HSCT from donors with past or undiagnosed lifethreatening illnesses or malignancies might be associated with an inferior recipient outcome. For the donors, the time from HSC donation to clinically manifest malignancies was short. Therefore, in some donors, the neoplasms might have antedated or relapsed before the HSC donation, remaining undetected as occult malignancies were not routinely screened for. 8 Fortunately, transmission of donor-derived malignancies during HSCT has not been reported. 9 However, recipient outcome of HSCT from donors with severe illnesses still appeared to be inferior. Older, weaker donors with previous malignancies might have reduced immunosurveillance, causing poorer post-HSCT immune recovery. Therefore, the putative graftversus-leukemia effect by donor-derived immunocompetent cells might also be weakened, accounting for the increased leukemic relapses. In line with this, none of the recipients of donors 1-5 had GVHD after HSCT or DLI. Another possibility is that desperate pre-HSCT conditions of the recipients necessitated the selection of donors with suboptimal health. In this situation, poor pre-HSCT risks would explain the inferior recipient outcome, and utilization of unfit donors the subsequent donor complications.
Although short-term donor problems are well-reported, information on long-term donor follow-up is scarce. 10 There are currently no data on long-term health issues for donors, as most transplantation centers do not follow-up donors prospectively. Nevertheless, HSC donation is not without risks. General anesthesia, physical trauma, hematopoietic growth factor for HSC mobilization and cytapheresis are immediate risks. 10 Furthermore, the long-term effects of HSC depletion and the ensuing hematopoietic regeneration remain unknown. Whether HSC donation might depress the immune system and accelerate the development of malignancies cannot be entirely excluded. Remarkably, three of the five dead donors underwent repeated leukapheresis after marrow donation, at 16, 22 and 40 months before death. With the use of elderly donors having underlying diseases, and repeated HSC collection for salvage procedures, the potential adverse immune effects on the donors constitute important practical and ethical issues. 11 Finally, when a recipient relapses after HSCT, it may be prudent to re-evaluate carefully the donor.
